BioHealth News Archive
Maryland Inno – Baltimore startup Vita Therapeutics raises $31M to advance treatment for genetic diseases
Baltimore's Vita Therapeutics announced the completion of a $31 million series B funding round on Wednesday, propelling the cell therapy company toward a clinical…
Read More
Is this really the second-best time ever to raise early-stage capital? | TechCrunch
“The 2022 venture capital market” is nearly a misnomer, as each quarter that passes seems to bring with it a new normal for startup…
Read More
Meet The NIA Entrepreneur-in-Residence (EIR)
We are so thankful for our Entrepreneurs-in-Residence (EIRs), who provide free business development guidance and counsel to assist #SmallBiz awardees with progress toward #commercialization…
Read More
Venture-Capital Firms Buy Up Public Tech Stocks as Startup Market Stalls – WSJ
Venture-capital firms are jumping into the stock market, buying up battered shares in publicly traded tech companies at a time when they are investing…
Read More
Diagnostics firm Bio-Rad in talks to merge with Qiagen – WSJ | Reuters
Oct 10 (Reuters) - California-based diagnostics company Bio-Rad Laboratories (BIO.N) is in talks to merge with Qiagen NV (QIA.DE), the Wall Street Journal reported…
Read More
BARDA Continues to Develop Public-Private Partnerships to Protect the Country · BioBuzz
Biotech and life sciences companies can benefit from partnering with the federal government in many ways, from funding to increased access to resources and…
Read More
Dr. Arti Santhanam: A Collaborative Scientist’s Passion Helps Build a Top-Five Tech-Based Entrepreneurial Community – Worlds Leaders
What does the Zulu word “ubuntu” have to do with a successful science and tech fund at Maryland’s TEDCO? To start, it’s been a…
Read More
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants
Oct 12, 2022 Homologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5 Study 307 (Lot…
Read More
BIO Announces Appointment of Rachel King as Interim CEO | Business Wire
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) – the world’s largest science and public advocacy organization, representing 1,000 members — announced today that Rachel King,…
Read More
Neuroene Therapeutics Wins 7th Annual BioHealth Capital Region Crab Trap Competition
Neuroene and Polaris Genomics benefit from increased prizes Did you miss the 7th Annual BioHealth Capital Region Crab Trap Competition? Below we aresharing a…
Read More
University of Maryland, Baltimore and Wexford Meeting Critical Demand for Wet Lab Space in Baltimore Region
Doubling the University of Maryland BioPark’s lab space, the two-phase 4MLK development project will represent more than $320 million in total capital investment BALTIMORE,…
Read More
Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial | Business Wire
GAITHERSBURG, Md--(BUSINESS WIRE)--Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases,…
Read More
NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)
The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases GAITHERSBURG, Md., Oct. 06, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI),…
Read More
Congress reauthorizes the SBIR/STTR Programs | SBIR.gov
WASHINGTON – Administrator Isabella Casillas Guzman, head of the U.S. Small Business Administration and voice for America’s 33 million small businesses in President Biden’s…
Read More
Industry Leaders Share Optimism on the Region’s Life Sciences Economic Outlook Amid Recession Concerns · BioBuzz
It’s no secret that a recession could hit the United States before the year ends. No one knows for sure yet, and many economists…
Read More